Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors

Dermatology

Volumn 222, Issue 2, 2011, Pages 144-147

  Gerber, Peter A ^a   Kukova, Gabriela ^a   Buhren, Bettina A ^a   Homey, Bernhard ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Demodex mites; Epidermal growth factor receptor, adverse effect; Erlotinib; Gefitinib; Infection; Rash

Indexed keywords

ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEMODEX; DEMODEX FOLLICULORUM; DEMODICOSIS; DENSITY; DRUG ERUPTION; DRUG INDUCED DISEASE; FEMALE; HUMAN; INFECTION SENSITIVITY; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD REVIEW; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN BIOPSY; SKIN DEFECT; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MITE INFESTATIONS; MITES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; ROSACEA; SKIN;

EID: 79955692259     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323001     Document Type: Article

References (35)

1. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
2. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048. (Pubitemid 350106711)
3. Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6: 803-812. (Pubitemid 44450468)
4. Gerber PA, Buhren BA, Cevikbas F, Bölke E, Steinhoff M, Homey B: Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010;63:163-165.
5. Gerber PA, Buhren BA, Homey B: More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011;364:486-487.
6. Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME: Impact and management of skin toxicity associated with anti- epidermal growth factor receptor therapy: survey results. Oncology 2007; 72: 152-159. (Pubitemid 351161602)
7. Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55: 657-670. (Pubitemid 44436627)
8. Bonnar E, Eustace P, Powell FC: The Demodex mite population in rosacea. J Am Acad Dermatol 1993; 28: 443-448. (Pubitemid 23075260)
9. Forton F, Germaux MA, Brasseur T, De Liever A, Laporte M, Mathys C, et al: Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol 2005; 52: 74-87. (Pubitemid 40038938)
10. Forton F, Seys B: Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993; 128: 650-659. (Pubitemid 23172024)
11. Marks R, Dawber RP: Skin surface biopsy: an improved technique for the examination of the horny layer. Br J Dermatol 1971; 84: 117-123.
12. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, et al: Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151: 238-241. (Pubitemid 39061311)
13. Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al: Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102: 47-53.
14. Grenader T, Gipps M, Goldberg A: Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008; 9: 59-60. (Pubitemid 351251603)
15. Kardaun SH, van Duinen KF: Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol 2008; 33: 46-49. (Pubitemid 350308526)
16. Li J, Peccerillo J, Kaley K, Saif MW: Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 2009; 10: 338-340.
17. Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC, et al: Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 2008; 26: 2779-2780.
18. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME: Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007; 109: 2182-2189. (Pubitemid 46805005)
19. Bolke E, Gerber PA, Lammering G, Peiper M, Muller-Homey A, Pape H, et al: Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008; 184: 105-110. (Pubitemid 351231657)
20. Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, et al: Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008; 66: 155-162.
21. Cholongitas E, Pipili C, Ioannidou D: Malassezia folliculitis presented as acneiform eruption after cetuximab administration. J Drugs Dermatol 2009; 8: 274-275.
22. Forton F, Song M: Limitations of standardized skin surface biopsy in measurement of the density of Demodex folliculorum: a case report. Br J Dermatol 1998; 139: 697-700. (Pubitemid 28474321)
23. Kocak M, Yagli S, Vahapoglu G, Eksioglu M: Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea: a randomized double-blind placebo- controlled study. Dermatology 2002; 205: 265-270. (Pubitemid 36158538)
24. Schaller M, Sander CA, Plewig G: Demodex abscesses: clinical and therapeutic challenges. J Am Acad Dermatol 2003; 49:S272-274. (Pubitemid 37314859)
25. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433. (Pubitemid 41222414)
26. Persi A, Rebora A: Metronidazole and Demodex folliculorum. Acta Derm Venereol 1981; 61: 182-183. (Pubitemid 11147578)
27. Banuls J, Ramon D, Aniz E, Jorda E, Torres V: Papular pruritic eruption with human immunodeficiency virus infection. Int J Dermatol 1991; 30: 801-803.
28. Dominey A, Rosen T, Tschen J: Papulonodular demodicidosis associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 1989; 20: 197-201. (Pubitemid 19055624)
29. Aquilina C, Viraben R, Sire S: Ivermectinresponsive Demodex infestation during human immunodeficiency virus infection: a case report and literature review. Dermatology 2002; 205: 394-397. (Pubitemid 35356769)
30. Redondo Mateo J, Soto Guzman O, Fernandez Rubio E, Dominguez Franjo F: Demodex -attributed rosacea-like lesions in AIDS. Acta Derm Venereol 1993; 73: 437. (Pubitemid 23351342)
31. Mascia F, Mariani V, Girolomoni G, Pastore S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003; 163: 303-312. (Pubitemid 36759615)
32. Gerber PA, Enderlein E, Homey B: The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 2008; 26: 2790-2792.
33. Basti S: Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007; 30:S10-16. (Pubitemid 47196597)
34. Gerber PA, Homey B: Images in clinical medicine: erlotinib-induced hair alterations. N Engl J Med 2008; 358: 1175. (Pubitemid 351398491)
35. Kheirkhah A, Casas V, Li W, Raju VK, Tseng SC: Corneal manifestations of ocular demodex infestation. Am J Ophthalmol 2007; 143: 743-749.